Aminoglycoside-induced hearing loss: South Africans at risk

South African Medical Journal

Volumn 99, Issue 6, 2009, Pages 440-441

  Bardien, Soraya ^a   de Jong, Greetje ^a   Schaaf, H Simon ^b   Harris, Tashneem ^c   Fagan, Johan ^c   Petersen, Lucretia ^d  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; CAPREOMYCIN; GENTAMICIN; KANAMYCIN; LOOP DIURETIC AGENT; MITOCHONDRIAL DNA; POLYPEPTIDE ANTIBIOTIC AGENT; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG POTENTIATION; EDITORIAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEARING LOSS; HUMAN; INNER EAR DISEASE; MULTIDRUG RESISTANT TUBERCULOSIS; NEPHROTOXICITY; OTOTOXICITY; PATIENT COMPLIANCE; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SHORT COURSE THERAPY; SOUTH AFRICA; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; TUBERCULOSIS CONTROL; VESTIBULAR DISORDER;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEARING LOSS; HUMANS; RISK FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 70049113462     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. World Health Organization. Global Tuberculosis Control - Surveillance, Planning, Financing. WHO Report 2008 WHO/HTM/TB/ 2008.393. http://www.who.int/tb/publications/global_report/2008/pdf/ annex_1.pdf (accessed 9 March 2009).
2. Department of Health. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. Pretoria: Department of Health. http://www.doh.gov.za/docs/factsheets/guidelines/mdrtb/index.html (accessed 9 March 2009).
3. Rybak LP, Ramkumar V. Ototoxicity. Kidney Int 2007; 72(8): 931-935.
4. Chen Y, Huang W-G, Zha D-J, et al. Aspirin attenuates gentamicin ototoxicity: From the laboratory to the clinic. Hear Res 2007; 226: 178-182.
5. Kokotas H, Petersen MB, Willems PJ. Mitochondrial deafness. Clin Genet 2007; 71(5): 379-391.
6. Xing G, Chen Z, Cao X. Mitochondrial rRNA and tRNA and hearing function. Cell Res 2007; 17(3): 227-239.
7. Gardner JC, Goliath R, Viljoen D, et al. Familial streptomycin ototoxicity in a South African family: a mitochondrial disorder. J Med Genet 1997; 34(11): 904-906.
8. American Academy of Pediatrics. Tuberculosis. In: Pickering LK, Baker CJ, Long SS, McMilan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases, 27th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2006: 678-704.
9. Bardien S, Human H, Harris T, et al. A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness. BMC Med Genet 2009; 10: 2.
10. Sha SH, Qiu JH, Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med 2006; 354(17): 1856-1857.